Insight Molecular Diagnostics

IMDX · NASDAQ

$3.03+$0.14 (+4.84%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.89

IMDX analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $9.86 (+225.4% upside)

Low: $8.08
Now: $3.03
High: $12.60

Upgrades and downgrades

The latest rating actions, newest first

IMDX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
LUCID CAPITAL MARKETS	Aug 24, 2026	Initiates	Buy	$8.00	25%
Needham	Aug 18, 2026	Maintains	Buy	$9.00	45%
Lake Street	Feb 17, 2026	Maintains	Buy	$8.00 → $12.00	27%
Needham	Nov 11, 2025	Maintains	Buy	$4.25 → $9.00	45%

The case for and against

Updated Feb 2, 2026

Bull case

Insight Molecular Diagnostics Inc. is poised for significant long-term revenue growth as it continues to advance its innovative diagnostic testing portfolio, particularly in the fields of organ transplant monitoring and cancer. The company’s addressable market could expand by approximately 10-20% through the inclusion of reimbursement for additional testing indications related to immunosuppression and rejection, which are currently under clinical evaluation. Additionally, drivers such as clinical data presentations, favorable guideline changes, and potential acceleration in revenue growth contribute to a positive outlook for the company's financial performance.

Bear case

Insight Molecular Diagnostics Inc. is facing significant financial challenges, as evidenced by a decline in gross margin from 67.6% to 53.5%, highlighting potential cost pressures despite exceeding estimates. The company's future revenue projections appear bleak, with expectations of minimal income from the GraftAssureIQ until mid-2026, pending IVD clearance for the GraftAssureDx. Additionally, several risks could exacerbate these financial concerns, including slower physician adoption of new tests, delays in insurer coverage, and increased cash burn rates, further contributing to a negative outlook for the company’s stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.